(RF), 1 LF+DF, 3 RF+DF and 1 LF+RF. Failed cases had similar rates of pretreatment PET (78%) and diagnostic biopsy (80%)
compared to the disease-free patients. Two patients with LF underwent salvage surgery; one pt with RF underwent salvage chemo/
surgery. The most common site of DF was lung (4/8 patients). The majority of patients did not receive chemotherapy due to the
signiﬁcant underlying comorbidities. Overall local control was 91% in 100 lesions (96 patients); estimated 1 year overall survival
(OS) was 83% (95% CI: 74% – 89%), 3 year OS 48% (95% CI: 32% – 62%); corresponding cause speciﬁc survival (CSS) was 93%
(95% CI: 87% – 98%) and 83% (95% CI: 72% – 94%), respectively. The estimated 3 year LF-free survival was 86% RF-free sur-
vival 90% and DF-free survival 77%. The most common acute toxicities were Grade 1 and 2 fatigue (42/96 patients); there were no
Grade 4 or 5 toxicities.
Our experience demonstrates high rates of local control and CSS and for patients with early stage NSCLC treated
with lung SBRT. Selected cases with local failure may be considered for salvage surgery.
Author Disclosure: M. Taremi, None; M. Dahele, None; T. Purdie, None; J. Bissonnette JP, None; S. Fung, None; A. Brade, None;
J. Cho, None; A. Hope, None; A. Sun, None; A. Bezjak, None.
Initial Toxicity Report of a Phase II Study of Radiofrequency Ablation Combined with External Beam
Radiation Therapy for Patients with Medically Inoperable Non–small Cell Lung Cancer (Stages IA and
J. J. Urbanic, H. P. Clark, C. Chiles, D. Case, W. H. Hinson, C. Hampton, W. T. Kearns, M. Crowley, P. Clark, A. W. Blackstock
Wake Forest University School of Medicine, Winston-Salem, NC
Hypofractionated radiotherapy (XRT) and radiofrequency ablation (RFA) have become monotherapy
treatment options for patients with Stage I lung cancer and lesions less than 4cm in size. We have undertaken a Phase II clinical
trial to evaluate the safety and toxicity of a combined treatment using both RFA and XRT. This is the ﬁrst toxicity report from that
Eligibility included age
18 years, ECOG PS 0–2, biopsy proven Stage I NSCLC, BAC excluded. Each
patient evaluated by a thoracic surgeon: deemed medically inoperable or refused surgery. Maximum tumor diameter 3.5 cm.
RFA treatment to gross disease using LeVeen electrode per manufacturer’s guideline. XRT started within 5 weeks after RFA
and CTV was post RFA abnormality on 4D CT/PET simulation. Radiotherapy dose either 7020 cGy, 26 fx, 270 cGy/fx using
3D techniques (3D) or 5400 cGy 3 fx (SBRT), 1800 cGy/fx using stereotactic bodyframe. SBRT allowed if post-RFA abnormality
4cm. Toxicity graded per NCI CTCAE v3.0.